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SUMMARY – We wanted to discuss our experiences in the approach to borderline ovarian tu-
mors, which constitute a group different from epithelial ovarian tumors with respect to their biological 
structure in line with retrospective information gathered from our cases. A total of 25 patients oper-
ated on for the indication of adnexal masses diagnosed as borderline ovarian tumors based on frozen 
section results were included in our study. Patient age, tumor diameter, tumor markers and surgeries 
performed were discussed in the light of the literature. Statistical analyses were performed using the 
SPSS software. The patient mean age was 43.84±11.34 years. The mass was localized in the right 
(n=13), left (n=11) or both (n=1) adnexal regions. The mean tumor diameter was 12.9±5.84 cm. His-
topathologic examination established the diagnosis of serous borderline (n=14 patients) and mucinous 
borderline (n=11) ovarian tumors. Although the results of our study are consistent with current litera-
ture data, a greater number of current studies should be performed on borderline ovarian tumors, 
which are defined as a class of tumors different from epithelial ovarian tumors.
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Introduction
The term borderline ovarian tumor (BOT), which 
accounts for 10%-20% of all epithelial ovarian tumors, 
was first used by Taylor et al. in 1929 for a group of 
completely different ovarian masses between benign 
and manifest malignant tumors as for its histologic 
and behavioral characteristics. During subsequent 
years, this definition was altered somewhat; in 1973, 
the International Federation of Gynecology and Ob-
stetrics (FIGO) introduced the term “tumor with low 
malignant potential” into the literature; and finally the 
World Health Organization defined these mass le-
sions as “borderline ovarian tumor (BOT)”, which is 
still used today1.
Histologic diagnosis of BOT is based on the crite-
ria described by Hart and Norris and detailed by Scul-
ly as follows: epithelial cellular proliferation (stratifica-
tion of the epithelial lining of the papillae, multi-layer-
ing of the epithelium, mitotic activity and nuclear 
atypia) without stromal invasion. Obvious stromal in-
vasion is the principal diagnostic criterion for BOT2. 
Although in recent years the definition of microinva-
sive BOT has been revived, it indicates a special sub-
classification. It is defined as the presence of stromal 
invasion of one or more than one foci smaller than 3 
mm or 10 mm2(3).
An important part of BOT has mucinous or serous 
histologic types; however, 4%-5% of these are clear 
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cell, endometrioid, mixed, transitional or Brenner type 
of tumors. Serous and mucinous borderline types com-
prise 43%-53% and 42%-52% of all BOTs, respective-
ly4. Approximately 30% of serous borderline tumors 
are bilateral, and frequently extraovarian invasion in 
the form of peritoneal implants is detected. The major-
ity of peritoneal implants are noninvasive, and invasive 
peritoneal implants are detected in nearly 30%-35% of 
cases. Although invasive implants may demonstrate 
disease progression, in most of the cases, surgical re-
section suffices. However, the incidence of bilaterality 
and extraovarian spread is lower in mucinous border-
line tumors5.
Standard surgical treatment in patients diagnosed 
with serous BOT on the basis of intraoperative frozen 
section examination consists of hysterectomy with bi-
lateral salpingo-oophorectomy (in young fertile pa-
tients, unilateral salpingo-oophorectomy and contra-
lateral ovarian biopsy to assess the opposite ovary), 
multiple peritoneal biopsies, and sampling from peri-
toneal irrigation fluid for cytologic evaluation. In mu-
cinous tumors, additional appendectomy should be 
performed. Although lymphadenectomy is not the 
currently recommended surgical treatment for BOT, it 
has been shown that even in cases with lymph node 
involvement, survival and recurrence rates have not 
changed6. Nowadays, studies demonstrating beneficial 
effects of adjuvant treatments such as chemotherapy 
and radiotherapy in patients with advanced stage BOT 
or invasive peritoneal implants are lacking. As it is 
known, patients with advanced stage BOT respond 
well to cisplatin-based adjuvant chemotherapeutic 
regimens, however, there is no favorable effect on long-
term survival7.
We analyzed the characteristic features of the pa-
tients operated in our department with the diagnosis 
of BOT in the light of the information summarized 
above and literature data. We believe that the data re-
trieved from our study would shed more light on di-
verse opinions on the issue, especially concerning 
treatment of these patients.
Patients and Methods
Patient selection
The study included 25 patients operated for ad-
nexal mass diagnosed as BOTs based on frozen section 
examination between 2011 and 2016 at Department 
of Gynecology and Obstetrics, Inönü University, Fac-
ulty of Medicine, Turgut Özal Medical Center. Preop-
erative levels of cancer antigen-125 (CA 125), carcino-
embryonic antigen (CEA), cancer antigen 19-9 (CA 
19-9) and cancer antigen 15-3 (CA 15-3) were mea-
sured in the patients. Location of the adnexal mass 
(right or left ovary), diameter, and histologic type of 
the tumor, analytical results of peritoneal irrigation 
fluid, the surgical procedure performed, results of peri-
toneal biopsy and number of pelvic/paraaortic lymph 
nodes were recorded. All patients were staged based on 
the FIGO classification system as revised in 2009. The 
mean patient follow-up period was 48±9.02 months.
Histopathologic evaluation
Serous borderline tumors display a hierarchical, 
branching architecture lined by cuboidal to columnar 
epithelium with minimal cytologic atypia. Many tu-
mors had a variable number of polygonal and hobnail 
cells with eosinophilic cytoplasm containing moder-
ately enlarged, hyperchromatic nuclei and sometimes 
nucleoli. Mucinous borderline tumors were lined by 
gastrointestinal-type epithelium in the form of gastric 
pyloric-type epithelium, goblet cells. The epithelium 
exhibited varying degrees of stratification, tufting and 
villous or slender filiform papillae. The cells showed 
mild to moderate nuclear enlargement, hyperchroma-
sia and sometimes pseudostratification, but high-grade 
nuclear features were not seen (Figs. 1 and 2).
Statistical analysis
Statistical analyses were performed using SPSS 
software (SPSS for Mac Inc., Chicago, IL, US). We 
computed descriptive statistics (mean and range).
Results
A total of 25 patients (mean age 43.84±11.34 years) 
with the diagnosis of BOT were included in the study. 
The youngest and oldest patients were aged 24 and 68 
years, respectively. All patients were diagnosed intra-
operatively as BOT based on frozen section examina-
tions, and subsequently the diagnosis was confirmed 
by examination of paraffin blocks. The examination of 
frozen sections established the diagnosis of serous or 
mucinous BOT with 100% accuracy. Intraoperative 
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exploration revealed mass lesions in the right (n=13), 
left (n=11), and both (n=1) adnexal regions. The mean 
tumor diameter was 12.9±5.84 cm (min 5 cm and max 
26 cm). Based on histopathologic examination, the 
 diagnosis of serous and mucinous BOT was made in 
14 and 11 patients, respectively.
During the preoperative period, the mean levels of 
CA 125, CEA, CA19-9 and CA 15-3 in all study pa-
tients were 63.19±93.8 U/mL (range 3.09-394 U/
mL), 31.29±76.63 U/mL, 20.83±11.24 U/mL (range 
6.40-48.60 U/mL) and 2.32±2.09 ng/mL (range 0.50-
10.8 ng/mL), respectively. The highest and lowest CA 
19-9 values measured in our patients were 0.60 U/mL 
and 382 U/mL, respectively.
Although laparoscopy and laparotomy as options 
were explained to the patients, laparotomic surgery 
was carried out according to the patient’s preference. 
In all patients undergoing surgery, peritoneal irrigation 
fluid was obtained as part of the surgical procedure. 
Cytologic examination of all samples obtained was re-
ported as having benign characteristics. All patients 
with the diagnosis of mucinous BOT underwent ap-
pendectomy, and malignancy was not observed in any 
specimen. Multiple peritoneal biopsies were obtained 
from all patients. Pelvic parietal peritoneum, perito-
neum of the Douglas pouch, mesentery of rectum and 
sigmoid colon, and abdominal parietal peritoneum 
were the preferred anatomical regions for sampling. 
Invasive or noninvasive metastatic implants were not 
Table 1. Characteristics of patients diagnosed with 












 1 50 12 Right Serous
 2 53 16 Right Serous
 3 52 24 Left Serous
 4 41 8 Left Serous
 5 62 6 Left Mucinous
 6 43 14 Left Mucinous
 7 50 11 Left Serous
 8 34 12 Right Mucinous
 9 48 8 Right Serous
10 52 24 Right Serous
11 25 26 Right Mucinous
12 46 12 Right Serous
13 45 10 Right Serous
14 34 8 Right Mucinous
15 42 15 Left Serous
16 48 18 Left Mucinous
17 46 21 Left Serous
18 51 6 Bilateral Serous
19 30 5 Left Mucinous
20 68 8 Right Mucinous
21 28 10 Left Serous
22 27 10 Left Mucinous
23 54 12 Left Mucinous
24 43 16 Right Serous
25 24 12 Left Mucinous
Fig. 1. Histologic appearance of serous borderline ovarian 
tumor (HEx40).
Fig. 2. Histologic appearance of mucinous borderline 
ovarian tumor (HEx40).

















 1 147 2.34 382 20.7 TAH + BSO + omentectomy + PPLND  
+ multiple peritoneal biopsies
24 26
 2 3.09 4.38 27.6 20.1 TAH + BSO + omentectomy + PPLND  
+ multiple peritoneal biopsies
17 22
 3 12.6 10.8 25.2 12.8 USO + contralateral ovarian biopsy  
+ multiple peritoneal biopsies
 4 7.86 3.24 88.8 31.4 TAH + BSO + omentectomy + PPLND  
+ multiple peritoneal biopsies
24 9
 5 10.6 1.4 31.4 48.6 TAH + BSO + multiple peritoneal biopsies  
+ appendectomy
 6 10.2 1.24 2.5 28.5 USO + contralateral ovarian biopsy + 
multiple peritoneal biopsies + appendectomy
 7 12.2 1.22 9.7 8.2 TAH + BSO + multiple peritoneal biopsies
 8 11.4 0.85 0.8 10.7 USO + contralateral ovarian biopsy + 
multiple peritoneal biopsies + appendectomy
 9 51.1 3.17 0.8 10.9 TAH + BSO + multiple peritoneal biopsies
10 10.8 1.85 1.2 6.4 TAH + BSO + multiple peritoneal biopsies
11 183.1 1.44 0.6 31.4 USO + contralateral ovarian biopsy + 
multiple peritoneal biopsies + appendectomy
12 6.86 0.74 12.1 7.82 TAH + BSO + omentectomy + PPLND  
+ multiple peritoneal biopsies
11 16
13 178.7 1.5 1.2 30.5 TAH + BSO + multiple peritoneal biopsies
14 20.0 1.74 2.5 10.4 USO + contralateral ovarian biopsy + 
multiple peritoneal biopsies + appendectomy
15 11.6 1.62 9.53 11.5 USO + contralateral ovarian biopsy  
+ multiple peritoneal biopsies
16 8.35 0.78 2.5 35.5 TAH + BSO + multiple peritoneal biopsies  
+ appendectomy
17 23.1 1.21 13.8 20.9 USO + contralateral ovarian biopsy  
+ multiple peritoneal biopsies
18 146 1.07 7.04 25.9 TAH + BSO + multiple peritoneal biopsies
19 16.9 2.04 47.4 8.8 USO + contralateral ovarian biopsy + 
multiple peritoneal biopsies + appendectomy
20 24.1 3.68 2.5 32.2 TAH + BSO + multiple peritoneal biopsies  
+ appendectomy
21 194 1.74 75.8 14.6 USO + contralateral ovarian biopsy  
+ multiple peritoneal biopsies
22 62.5 0.5 2.5 18.6 USO + contralateral ovarian biopsy + 
multiple peritoneal biopsies + appendectomy
23 12.5 4.54 2.5 25.8 TAH + BSO + multiple peritoneal biopsies  
+ appendectomy
24 394 3.32 23.2 36.2 TAH + BSO + omentectomy + PPLND  
+ multiple peritoneal biopsies
17 26
25 21.4 1.66 9.08 12.4 USO + contralateral ovarian biopsy + 
multiple peritoneal biopsies + appendectomy
CA 125 = cancer antigen 125; Ca 19-9 = cancer antigen 19-9; CA 15-3 = cancer antigen 15-3; CEA = carcinoembryonic antigen; TAH = 
total abdominal hysterectomy; BSO = bilateral salpingo-oophorectomy; PPLND = pelvic-paraaortic lymphadenectomy; USO = unilateral 
salpingo-oophorectomy
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detected in peritoneal biopsy specimens. Patients in 
their reproductive age underwent fertility-preserving 
surgeries. Five fertile patients underwent total abdom-
inal hysterectomy together with bilateral salpingo-oo-
phorectomy, pelvic and paraaortic lymphadenectomy, 
and omentectomy. Nine patients underwent total ab-
dominal hysterectomy and omentectomy. Eleven pa-
tients underwent unilateral salpingo-oophorectomy 
and contralateral ovarian biopsy procedures.
Lymphadenectomy procedure was performed sys-
tematically via dissection over obturator nerve in pel-
vis, bilaterally up to the renal vein in the paraaortic 
region. The mean number of pelvic and paraaortic 
lymph nodes was 18.6±5.50 (range 11-24) and 
19.8±7.29 (range 9-26), respectively. Lymph nodes in 
the pelvic and paraaortic regions were not pathologic. 
All patients were staged based on the FIGO classifica-
tion system as revised in 2009, and they were evaluated 
as stage IA patients. In order to compare cytoreductive 
and conservative surgery in the treatment of BOTs, 
systematic lymphadenectomy was performed in five 
patients. Adjuvant chemotherapy and/or adjuvant sur-
gery was not required. During two years of follow-up, 
there was no disease recurrence. Patient characteristics 
are summarized in Tables 1 and 2.
Discussion
In BOTs, atypical epithelial proliferation without 
stromal invasion is detected; these tumors are diag-
nosed based on histopathologic criteria and account 
for 10%-15% of all epithelial ovarian tumors. Because 
of their atypical structures, they are classified in a 
group other than epithelial ovarian tumors8. In es-
sence, BOTs differ greatly from epithelial ovarian tu-
mors, at least with respect to their age at onset and 
prognosis. When compared with ovarian cancers, 
BOTs are seen at an earlier age. Besides, even in cases 
with detected peritoneal invasion, the mean survival 
times are longer relative to epithelial ovarian tumors. 
The 5- and 10-year survival rates for BOT stage I, II 
and III were 99%, 97% and 98% vs. 90%, 96% and 
88%, respectively5. Still, the great majority of these are 
diagnosed at an early stage. Contrary to epithelial 
ovarian tumors, most of them are detected when they 
are contained in a single ovary at a noninvasive stage. 
In a meta-analysis exploring data on 6362 patients di-
agnosed with BOT, 78.9% of the cases had been diag-
nosed as FIGO stage I4. In accordance with literature 
findings, the patient mean age in our study was 
43.84±11.34 years. The youngest patient was aged 24 
years, while seven patients were aged less than 40. All 
our study patients were evaluated as stage IA, and no 
disease recurrence was detected in all patients within 
two years.
Histologically important part of the cases with 
BOT are mucinous or serous tumors, however, clear 
cell, endometrioid, mixed, transitional or Brenner type 
tumors are detected in 4%-5% of cases. Serous border-
line and mucinous histologic subtypes comprise 43%-
53% and 42%-52% of all BOTs, respectively5. In our 
study, serous and mucinous BOTs were diagnosed in 
14 and 11 patients, respectively. BOTs were located in 
the right (n=13), left (n=11) or both (n=1) adnexal 
 regions.
Preoperative evaluation of BOTs is still a controver-
sial issue. Relevant data cannot be found especially on 
serum tumor markers. In a study performed by Van 
Calster et al., the authors demonstrated that since se-
rum CA125 levels increase in BOTs and early-stage 
epithelial ovarian tumors, the use of this parameter in 
preoperative evaluation would not be appropriate9. In 
another study, increased serum CA125 levels were re-
corded in 40% of the patients diagnosed as stage 1 
BOT and 83% of those with advanced-stage BOT10. 
However, studies on other serum tumor markers in-
cluding CA19-9, CA15-3 and CEA are not available11. 
In our study, we detected higher serum CA-125 levels 
in eight patients (upper limit of normal=35 U/mL)
Serous BOTs especially tend to spread through 
peritoneal metastases rather than lymphatic route. 
These peritoneal metastases demonstrate noninvasive 
and invasive characteristics. Noninvasive peritoneal 
implants constitute 85% of peritoneal metastases, 
however, evidence for stromal invasion cannot be de-
tected in biopsy specimens12. Noninvasive peritoneal 
implants histopathologically demonstrate epithelial or 
desmoplastic features. However, prognosis is similar in 
both types. Still, as demonstrated in various studies, 
since desmoplastic noninvasive implants have a more 
complex structure, they have a higher potential for 
stromal microinvasion13. The mean survival times of 
patients with peritoneal implants are adversely affect-
ed. Mortality rates of 4.7% and 34% have been report-
ed for patients with invasive and noninvasive perito-
neal implants, respectively14. The presence of micro-
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papillary structure is another aspect of serous BOTs. 
The presence of this structure affects prognosis ad-
versely, however, the main problem is increase in the 
rates of invasive recurrence in patients with micropap-
illary structure15. In their study, Shih et al. demonstrat-
ed that during 4 years of follow-up, the rates of inva-
sive recurrences were higher and naturally disease-free 
survival rates significantly lower in patients with mi-
cropapillary structure when compared with those 
without micropapillary structure (75.9% vs. 94.3%)16. 
The presence of stromal microinvasion in serous bor-
derline tumors has become a debatable issue. Microin-
vasion has been defined as the presence of invasion of 
less than 3 mm or 10 mm2 in one or more than one 
focus17. Although it is still a debatable issue whether 
the risk of invasive recurrence increases in cases with 
microinvasion, literature surveys indicate that micro-
invasive structure is recognized as a prognostic factor 
for serous BOT12. In our study, microinvasive and mi-
cropapillary structure was not detected in 14 patients 
diagnosed as serous BOT. Besides, invasive or nonin-
vasive formations were not observed in peritoneal bi-
opsies. Intraepithelial carcinoma, which is associated 
with higher recurrence rates and used to describe mu-
cinous BOTs, is currently considered a debatable con-
cept by many authors. Histopathologically, a consensus 
has been reached concerning its relationship with se-
vere epithelial dysplasia that does not penetrate be-
yond basal membrane. Indeed, in a case series ana-
lyzed, the risk of recurrence in mucinous borderline 
tumors containing foci of intraepithelial carcinoma 
was unexpectedly high for this group of tumors18. The 
term of stromal microinvasion defined for serous bor-
derline tumors based on diagnostic criteria also holds 
true for mucinous BOTs. However, in a large-scale 
case series, the authors demonstrated that the presence 
of microinvasion in mucinous tumors was not associ-
ated with the frequency of invasive recurrences and 
prognosis19. In our study, intraepithelial carcinoma and 
stromal invasion were not detected in 11 patients diag-
nosed with mucinous BOT.
Surgical alternative defined and accepted for the 
treatment of BOTs should be unilateral/bilateral sal-
pingo-oophorectomy and hysterectomy if necessary. 
Surgical staging is realized through peritoneal sam-
pling or lymph node dissection12. We did not take a 
standard criterion for lymphadenectomy; these pa-
tients underwent systematic lymphadenectomy. Since 
these tumors are observed at an early age, conservative 
treatment alternative (unilateral ovary and/or uterus 
sparing surgeries) can be applied in patients of fertile 
age. It should not be forgotten that fertility sparing 
surgery is an appropriate preference for patients in 
whom peritoneal implant is detected. In a meta-anal-
ysis of outcomes in nearly 2000 patients, higher recur-
rence rates were demonstrated for patients having un-
dergone bilateral salpingo-oophorectomy when com-
pared to those with hysterectomy with bilateral salpin-
go-oophorectomy. However, it has also been reported 
that this condition does not imply an adverse effect on 
survival rates, and a redo-surgical excision could be 
performed successfully20. In another study, recurrence 
rates were 12%-58% in patients diagnosed with BOT 
and having undergone conservative surgery (cystecto-
my), whereas in the group having undergone extensive 
surgery (bilateral salpingo-oophorectomy) recurrence 
rates ranged between 0 and 20%1.
Lymph node involvement was reported in 25% of 
patients with advanced stage BOTs (FIGO stages III 
and IV). Molecular and histologic data obtained from 
cases with lymph node metastases support the pres-
ence of a synchronized ovarian tumor21. Many studies 
have demonstrated that lymph node involvement in 
patients diagnosed with BOT did not exert an adverse 
effect on survival times12. In a similar study, Kanat-
Pektas et al. stated that lymphadenectomy could not be 
performed as a surgical treatment in cases diagnosed 
with BOT considering the lack of any significant dif-
ference in survival times between the groups having 
and having not undergone lymphadenectomy22. In our 
study, we used fertility-sparing surgeries (unilateral 
salpingo-oophorectomy, contralateral ovarian biopsy, 
and multiple peritoneal sampling) in 11 patients. After 
long-term follow-up, we did not detect any recurrenc-
es in our patients. In patients with preoperatively in-
creased serum tumor marker levels and large (≥15 cm) 
ovarian tumors, where we palpated retroperitoneal 
lymph nodes during intraoperative period, we system-
atically applied lymphadenectomy procedures. We 
used this surgical procedure in five patients, but we 
could not detect any metastatic lymph node.
Since a significant proportion of patients diag-
nosed with BOT are young women and have a desire 
to give birth, laparoscopic surgical intervention should 
be considered. However, when the risks of cyst rupture, 
intraperitoneal dissemination of tumor cells and tu-
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mor metastases to trocar incision were considered, 
laparotomy was thought to be more advantageous12. 
Studies performed have shown that the risks of cyst 
rupture and recurrence were greater when compared 
with laparotomic approach23. It should be noted that 
eight cases with trocar metastases detected during 
postoperative period are described in the literature24. 
We applied laparotomic surgery in all of our study 
 patients.
In conclusion, BOTs have completely different bi-
ological characteristics from epithelial ovarian tumors 
with respect to tumor behavior and prognosis. For 
these tumors, which are mostly detected in young 
women at an early stage, fertility-sparing surgeries can 
be applied. The pathogenesis and treatment of these 
tumors are still debatable issues, and a greater number 
of studies should be available in the literature. Within 
this context, we believe that our study would shed 
some new light on these controversial issues.
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RETROSPEKTIVNA ANALIZA GRANIČNIH TUMORA JAJNIKA:  
ISHODI U JEDNOM CENTRU
E. Yilmaz, N. Sahin, I. Koleli, R. Melekoglu, E. Tanrikut, S. Faydali, A. Karaer i E. Inci Coskun
Želja nam je opisati naša iskustva u pristupu graničnim tumorima jajnika kao skupini tumora koji se razlikuju od epitel-
nih tumora jajnika prema biološkoj strukturi, sukladno retrospektivnim podacima prikupljenim iz naših slučajeva. U istraži-
vanje je bilo uključeno 25 bolesnica operiranih pod indikacijom adneksnih tvorevina dijagnosticiranih kao granični tumori 
jajnika na osnovi rezultata dobivenih iz zamrznutih uzoraka. Prikazani su sljedeći podaci bolesnica: dob, promjer tumora, 
tumorski biljezi i izvedeni operativni zahvati, u odnosu na literaturne podatke. Statistička analiza je provedena primjenom 
programa SPSS. Srednja dob bolesnica bila je 43,84±11,34 godine. Tumorska masa bila je smještena u desnoj (n=13) ili lije-
voj (n=11) adneksnoj regiji, a kod jedne bolesnice u objema adneksnim regijama. Srednji promjer tumora bio je 12,9±5,84 
cm. Histopatološkom analizom postavljena je dijagnoza seroznog graničnog (n=14) i mucinoznog graničnog (n=11) tumora 
jajnika. Iako su rezultati ovoga istraživanja sukladni literaturnim podacima, potrebno je provesti veći broj studija graničnih 
tumora jajnika, koji se definiraju kao vrsta tumora različita od epitelnih tumora jajnika.
Ključne riječi: Ovarijski tumori – dijagnostika; Ovarijski tumori – klasifikacija; Cistadenokarcinom, serozni – dijagnostika; 
Karcinom, ovarijski epitelni – dijagnostika
